首页|某院新型冠状病毒感染前后临床病原菌分布特征及耐药性变化研究

某院新型冠状病毒感染前后临床病原菌分布特征及耐药性变化研究

扫码查看
目的 探讨新型冠状病毒(COVID-19)感染前后安徽省某三甲医院临床病原菌的分布情况及其耐药性变迁,为医院感染的防控及临床合理使用抗菌药物提供参考.方法 回顾性分析2017年1月1日—2019年12月31日(2017-2019年组)、2020年1月1日—2022年12月31日(2020-2022年组)医院所有送检标本中病原菌的临床分布及对临床常用抗菌药物的耐药性进行统计学分析.结果 2017-2022年共分离出34734株细菌,其中2017-2019年组占比40.95%,2020-2022年组占比59.05%,均以革兰阴性菌为主.2020-2022年组肺炎克雷伯菌、大肠埃希菌和铜绿假单胞菌占比升高,鲍曼不动杆菌和金黄色葡萄球菌占比较2017-2019年组下降,差异具有统计学意义(均P<0.05).肺炎克雷伯菌和大肠埃希菌对碳青霉烯类抗菌药物较敏感,耐药率均<10%,2020-2022年组肺炎克雷伯菌对亚胺培南、厄他培南耐药率较2017-2019年组升高,差异具有统计学意义(均P<0.05);2020-2022年组鲍曼不动杆菌对头孢吡肟、庆大霉素耐药率均下降(均P<0.05);2020-2022年组铜绿假单胞菌对亚胺培南、头孢类、喹诺酮类药物的耐药率均升高(均P<0.05);2020-2022年组金黄色葡萄球菌对多数抗菌药物的耐药率均下降(均P<0.05),未检出对万古霉素和利奈唑胺耐药的菌株.耐碳青霉烯类铜绿假单胞菌、耐碳青霉烯类肺炎克雷伯菌、耐碳青霉烯类大肠埃希菌检出率较2017-2019年升高,而耐甲氧西林金黄色葡萄球菌检出率较2017-2019年下降(均P<0.05).结论 2020-2022年医院分离细菌耐药性较2017-2019年发生了较大变化,其中肺炎克雷伯菌、铜绿假单胞菌对碳青霉烯类的耐药率持续上升,应引起临床高度重视.
Study on the distribution characteristics and drug resistance changes of clinically isolated bacteria before and after the outbreak of COVID-19 in a hospital
Objective To explore the distribution and drug resistance change of clinically isolated bacteria in a tertiary hospital in Anhui Province before and after the outbreak of Corona Virus Disease 2019(COVID-19),as well as to provide reference for the prevention and control of hospital-acquired infection and the rational use of antimicrobial agents in clinical practice.Methods The clinical distribution of bacteria and their resistance to commonly used clinical antimicrobial agents from all specimens sent by the hospital were retrospectively analyzed statistically in the 2017-2019 group(from January 1st of 2017 to December 31st of 2019)and the 2020-2022 group(from January 1st of 2020 to December 31st of 2022).Results A total of 34,734 strains of bacteria were isolated from 2017 to 2022,with 40.95%in the 2017-2019 group and 59.05%in the 2020-2022 group,all of which were predominantly Gram-negative bacteria.Compared with the 2017-2019 group,proportions of Klebsiella pneumoniae,Escherichia coli and Pseudomonas aeruginosa increased in the 2020-2022 group,whereas proportions of Acinetobacter baumannii and Staphylococcus aureus decreased,and the difference was statistically significant(all P<0.05).Klebsiella pneumoniae and Escherichia coli were sensitive to carbapenems;antimicrobial resistance rates were all smaller than 10%.The resistance rate of Klebsiella pneumoniae to imipenem and ertapenem increased in the 2020-2022 group,and the difference was statistically significant(all P<0.05).The resistance rate of Acinetobacter baumannii to cefepime and gentamicin decreased in the 2020-2022 group(all P<0.05).The resistance rate of Pseudomonas aeruginosa to imipenems,cephalosporins and quinolones increased in the 2020-2022 group(all P<0.05).The resistance rate of Staphylococcus aureus to most antimicrobial agents decreased(all P<0.05).Vancomycin-resistant and linezolid-resistant strains were not found.Detection rates of carbapenem-resistant Pseudomonas aeruginosa,carbapenem-resistant Klebsiella pneumoniae,and carbapenem-resistant Escherichia coli increased compared to the 2017-2019 group,whereas methicillin-resistant Staphylococcus aureus decreased compared to the 2017-2019 group(all P<0.05).Conclusion Compared to 2017-2019,the antimicrobial resistance changed significantly in 2020-2022.The resistance rate of Klebsiella pneumoniae and Pseudomonas aeruginosa to carbapenems continued to rise,which should be highly valued in clinical practice.

Corona virus disease 2019Clinical isolated bacteriaAntimicrobial agentDrug resistance

张培金、唐丽玲、杨正海

展开 >

皖南医学院第一附属医院感染管理科,芜湖 241001

皖南医学院第一附属医院检验科,芜湖 241001

新型冠状病毒感染 临床分离菌 抗菌药物 耐药性

2024

中国抗生素杂志
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

中国抗生素杂志

CSTPCD北大核心
影响因子:1.08
ISSN:1001-8689
年,卷(期):2024.49(11)